Dyne Therapeutics, Inc. 4

Atlas-affiliated funds for which insider Jason P. Rhodes is a managing member sold multiple blocks of Dyne Therapeutics (DYN) common stock totaling several hundred thousand shares at around $23 per share under a Rule 10b5‑1 plan.

On July 6–7, 2026, reporting person Jason P. Rhodes, in his capacity related to various Atlas Venture funds, reported a series of open‐market sales of Dyne Therapeutics, Inc. common stock pursuant to a pre‑established Rule 10b5‑1 trading plan adopted on March 19, 2026. The transactions comprised sales totaling 253,039, 127,182 and 100,019 shares on July 6 at a weighted average price of $22.79, followed by multiple sales on July 7 of 124,379, 29,587, 62,543, 14,844, 49,193, 11,665 and 5,000 shares at weighted average prices of $23.17, $23.62, $23.17, $23.62, $23.17, $23.62 and $23.61, respectively, with actual execution prices falling within detailed price ranges disclosed in the footnotes. After these fund‑level sales, indirect holdings reported for the Atlas Venture entities remained in the multi‑million‑share range, and Rhodes disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, indicating these trades represent ongoing portfolio management activity by the venture funds rather than personal discretionary selling.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

fda

Accession

0001577014-26-000014

Alert Tier

7